NOW APPROVED FOR PATIENTS IN THE U.S.
Learn More ›

2019 Makes it 5x in a Row

We’re thrilled to be named a Top Place to Work for a 5th straight year by the Boston Globe.

To those who say “impossible, impractical, unrealistic,” we say:

Challenge Accepted

We’re relentless in our pursuit of new treatments because patients shouldn't have to wait for hope.

Rose, living with acute
 hepatic porphyria

We are developing a new class of innovative medicines called

RNAi Therapeutics

that we believe have the potential to transform the lives of people living with rare diseases.

Dane, living with
 hATTR amyloidosis

We’re committed to
ensuring broad patient

Access to our medicines

for those who may benefit from them.

Cece, living with
 hATTR amyloidosis

We are focused on diseases for which treatment options are limited or simply don't exist.

Our Robust Pipeline

includes investigational RNAi therapeutics for rare genetic, cardio-metabolic, hepatic infectious, and CNS and ocular diseases.

APPROVED FOR PATIENTS IN THE U.S.
Learn More ›

LATEST NEWS

Alnylam Is the Leading RNAi Therapeutics Company

 

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, our first medicine, ONPATTRO® (patisiran), became the world’s first approved RNAi therapeutic. Our second medicine, GIVLAARITM (givosiran), was approved by the FDA in 2019. We are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases.

 

Learn More About Alnylam ›

Alnylam by the Numbers

>1k
Employees
16
Countries
10
Programs Currently in Clinical Development
2
Approved Products*
>35
Clinical Studies to Date
>5yrs
Longest Duration of Exposure

Updated as of November 2019
* 2 approved in the U.S., 1 of which is approved in the European Union, Canada, and Japan

 
 
 
 
>1k
 
 
Employees
 
 
 
 
16
 
 
Countries
 
 
 
 
10
 
 
Programs Currently in
Clinical Development
 
 
 
 
2
 
 
Approved Products*
 
 
 
 
>35
 
 
Clinical Studies
to Date
 
 
 
 
>5yrs
 
 
Longest Duration
of Exposure

Updated as of November 2019
* 2 approved in the U.S., 1 of which is approved in the European Union, Canada, and Japan

OUR FOCUS ON PATIENTS

 

Patients are at the core of everything we do. Alnylam was founded to help people who lack adequate treatment options live fuller, healthier lives. Their needs drive our discoveries, and their stories further our commitment to delivering innovative therapies.

A Family Living with
 hATTR Amyloidosis

Candace: Living with
Porphyria

A Family Living with
Primary Hyperoxaluria Type 1 (PH1)

OUR PIPELINE & PLATFORMS

Our robust pipeline contains therapies in late-stage (Phase 3) and early-stage (Phase 2 or earlier) trials. Our RNAi therapies leverage two distinct approaches to enable delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates.

Late Stage

Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, hypercholesterolemia, and primary hyperoxaluria type 1.

 

See Our Late-Stage RNAi Therapies ›

Early Stage

Learn more about our investigational therapies across multiple disease areas.

 

See Our Early-Stage RNAi Therapies ›

CAREERS @ALNYLAM

Join Us

We are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles. We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted” to our mission.

View Job Openings ›

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.